When AbbVie ABBV -5.66%’s CEO Rick Gonzalez described his recently acquired product ibrutinib (“Imbruvica”) as offering “a pipeline in a drug,” I imagine every business development executive in biopharma chuckled. No question – each of them has used this exact line at some point to characterize a partner-ready product that has been developed for one indication, yet just might be useful in a range of others.
Hey, check out all the research scientist jobs. Post your resume today!
